EP Patent

EP3760629A1 — Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate

Assigned to Adverio Pharma GmbH · Expires 2021-01-06 · 5y expired

What this patent protects

The present invention relates to forms of methyl {4.6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3.4-b]pyridino-3-yl]pyrimidino-5-yl}methylcarbamate comprising its Modification I, mono-DMSO solvate, sesqui-DMSO solvate and 1/4-ethyl acetate solvate and combinations thereof.

USPTO Abstract

The present invention relates to forms of methyl {4.6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3.4-b]pyridino-3-yl]pyrimidino-5-yl}methylcarbamate comprising its Modification I, mono-DMSO solvate, sesqui-DMSO solvate and 1/4-ethyl acetate solvate and combinations thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP3760629A1
Jurisdiction
EP
Classification
—
Expires
2021-01-06
Drug substance claim
No
Drug product claim
No
Assignee
Adverio Pharma GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.